CUSIP No. 60877T 10 1 Page 1 of 8 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------------
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILES PURSUANT
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 1)[1]
Momenta Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.0001 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
60877T 10 1
--------------------------------------------------------------------------------
December 31, 2005
Date of Event Which Requires Filing of this Statement
Check the appropriate box to designate the rule pursuant to which this Schedule
is Filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ X ] Rule 13d-1(d)
-----------------------
[1]The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act.
CUSIP No. 60877T 10 1 Page 2 of 8 Pages
--------------------------------------------------------------------------------
1) Name of Reporting Person MVM International Life
I.R.S. Identification Sciences Fund No. 1, L.P.
No. of Above Person
(Entities Only)
--------------------------------------------------------------------------------
2) Check the Appropriate Box (a) [ X ]
if a Member of a Group (b) [ ]
--------------------------------------------------------------------------------
3) SEC Use Only
--------------------------------------------------------------------------------
4) Citizenship or Place United Kingdom
of Organization
--------------------------------------------------------------------------------
Number of 5) Sole Voting
Shares Beneficially Power -0-
Owned by Each
Reporting Person
With
----------------------------------------------------
6) Shared Voting 1,610,850 shares
Power of Common Stock
----------------------------------------------------
7) Sole Disposi-
tive Power -0-
----------------------------------------------------
8) Shared Dis- 1,610,850 shares
positive Power of Common Stock
----------------------------------------------------
9) Aggregate Amount Beneficially 1,610,850 shares
Owned by Each Reporting person of Common Stock
--------------------------------------------------------------------------------
10) Check if the Aggregate
Amount in Row (9)
Excludes Certain Shares
--------------------------------------------------------------------------------
11) Percent of Class
Represented by 5.3%
Amount in Row (9)
--------------------------------------------------------------------------------
12) Type of Reporting
Person PN
-2-
CUSIP No. 60877T 10 1 Page 3 of 9 Pages
--------------------------------------------------------------------------------
1) Name of Reporting Person MVM Life Science
I.R.S. Identification Partners LLP
No. of Above Person
(Entities Only)
--------------------------------------------------------------------------------
2) Check the Appropriate Box (a) [ X ]
if a Member of a Group (b) [ ]
--------------------------------------------------------------------------------
3) SEC Use Only
--------------------------------------------------------------------------------
4) Citizenship or Place United Kingdom
of Organization
--------------------------------------------------------------------------------
Number of 5) Sole Voting
Shares Beneficially Power -0-
Owned by Each
Reporting Person
With
----------------------------------------------------
6) Shared Voting 8,656 shares
Power of Common Stock
----------------------------------------------------
7) Sole Disposi-
tive Power -0-
----------------------------------------------------
8) Shared Dis- 8,656 shares
positive Power of Common Stock
----------------------------------------------------
9) Aggregate Amount Beneficially 8,656 shares
Owned by Each Reporting person of Common Stock
--------------------------------------------------------------------------------
10) Check if the Aggregate
Amount in Row (9)
Excludes Certain Shares
--------------------------------------------------------------------------------
11) Percent of Class
Represented by less than 0.1%
Amount in Row (9)
--------------------------------------------------------------------------------
12) Type of Reporting
Person OO
-3-
CUSIP No. 60877T 10 1 Page 4 of 8 Pages
Amendment No. 1 to Schedule 13G
---------------------------------
Reference is hereby made to the statement on Schedule 13G originally
filed with the Securities and Exchange Commission on January 27, 2005 (the
"Schedule 13G".) Terms defined in the Schedule 13G are used herein as so
defined.
The following Items of the Schedule 13G are hereby amended and restated
to read in their entirety as follows:
Item 2(a) - Name of Person Filing:
MVM International Life Sciences Fund No. 1, L.P.
("MVM Fund No. 1")
MVM Life Science Partners LLP ("MVM")
Item 4 - Ownership.
(a) Amount Beneficially Owned:
MVM Fund No. 1: 1,610,850 shares of Common Stock
MVM : 8,656 shares of Common Stock
(b) Percent of Class:
MVM Fund No. 1: 5.3%
MVM: less than 0.1%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: -0-
(ii) shared power to vote or to direct the vote:
MVM Fund No. 1: 1,610,850 shares of Common Stock
MVM: 8,656 shares of Common Stock
(iii) sole power to dispose or to direct the
disposition of: -0-
(iv) shared power to dispose or to direct the disposition of:
MVM Fund No. 1: 1,610,850 shares of Common Stock
MVM: 8,656 shares of Common Stock
-4-
CUSIP No. 60877T 10 1 Page 5 of 8 Pages
Item 8 - Identification and Classification of Members of the Group:
See Exhibit 2.
-5-
CUSIP No. 60877T 10 1 Page 6 of 8 Pages
Signature:
After reasonable inquiry and to the best of their knowledge
and belief, the undersigned certify that the information set forth in this
statement is true, complete and correct.
MVM INTERNATIONAL LIFE SCIENCES FUND NO. 1, L.P.
By /s/ Thomas Casdagli
---------------------
Director of Finance
MVM LIFE SCIENCE PARTNERS LLP
By /s/ Thomas Casdagli
---------------------
Member
Date: January 17, 2006
-6-
CUSIP No. 60877T 10 1 Page 7 of 8 Pages
EXHIBIT 1
AGREEMENT OF
MVM INTERNATIONAL LIFE SCIENCES
FUND NO. 1, L.P.
AND MVM LIFE SCIENCE PARTNERS LLP
PURSUANT TO RULE 13d-1(f)
-------------------------------
The undersigned hereby agree that the Information Statement on
Schedule 13G to which this Agreement is annexed as Exhibit 1 is filed on behalf
of each of them in accordance with provisions of 13d-1(f) under the Securities
Exchange Act of 1934, as amended.
MVM INTERNATIONAL LIFE SCIENCES FUND NO. 1, L.P.
By /s/ Thomas Casdagli
---------------------
Director of Finance
MVM LIFE SCIENCE PARTNERS LLP
By /s/ Thomas Casdagli
---------------------
Member
Date: January 17, 2006
-7-
CUSIP No. 60877T 10 1 Page 8 of 8 Pages
EXHIBIT 2
Identification and Classification
of Members of the Group
----------------------------------
MVM International Life Sciences Fund No. 1, L.P. and MVM Life Science
Partners LLP are filing this statement on Schedule 13G as a group.
MVM International Life Sciences Fund No. 1, L.P. is a United Kingdom
limited partnership. MVM Life Science Partners LLP is a limited liability
partnership organized in the United Kingdom. MVM Life Science Partners LLP is
the discretionary investment manager of MVM International Life Sciences Fund No.
1, L.P.
-8-